Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Adaptimmune Therapeutics's total assets was $130.63M at Jun 30, 2025. For fiscal 2024 it was $245.96M, down 13.0% from the year before. The highest annual figure on record is $469.55M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $245.96M | -13.0% |
| FY2023 | Dec 31, 2023 | $282.62M | -14.1% |
| FY2022 | Dec 31, 2022 | $328.92M | -30.0% |
| FY2021 | Dec 31, 2021 | $469.55M | +4.1% |
| FY2020 | Dec 31, 2020 | $451.14M | +148.5% |
| FY2019 | Dec 31, 2019 | $181.54M | -34.4% |
| FY2018 | Dec 31, 2018 | $276.74M | -1.6% |
| FY2017 | Dec 31, 2017 | $281.15M | -6.5% |
| FY2015 | Jun 30, 2015 | $300.65M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $130.63M | -59.4% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $158.07M | -38.7% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $245.96M | -13.0% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $317.44M | +7.0% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $321.70M | -6.2% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $258.01M | -10.4% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $282.62M | -14.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $296.64M | -10.7% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $342.98M | -11.7% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $288.08M | -31.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $328.92M | -30.0% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $332.20M | -6.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $388.27M | -0.4% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $419.80M | +2.0% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $469.55M | +4.1% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $353.53M | -26.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $389.79M | -23.9% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $411.58M | +44.3% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $451.14M | +148.5% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $479.02M | +130.0% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $512.20M | +113.8% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $285.24M | +5.5% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $181.54M | -34.4% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $208.25M | -32.7% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $239.52M | +13.4% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $270.44M | +9.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $276.74M | -1.6% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $309.63M | +2.7% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $211.30M | -25.7% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $247.07M | -7.1% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $281.15M | -6.5% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $301.38M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $284.28M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $265.98M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $300.65M | – |
See a number that looks wrong?